Mesoblast Ltd Files Quarterly Report
Ticker: MEOBF · Form: 6-K · Filed: Oct 22, 2025 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Oct 22, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: quarterly-report, biotech, financials
TL;DR
MESO dropped its Q3 report, check financials and ops.
AI Summary
Mesoblast Limited filed a quarterly report (Appendix 4C) with the Australian Securities Exchange on October 20, 2025, for the quarter ended September 30, 2025. The report details the company's financial activities and operational updates for that period. Mesoblast Limited is incorporated in Australia and its principal executive offices are located in Melbourne.
Why It Matters
This filing provides investors with a snapshot of Mesoblast's financial health and operational progress during the specified quarter, crucial for understanding the company's performance and future outlook.
Risk Assessment
Risk Level: medium — As a biotechnology company, Mesoblast operates in a highly regulated and research-intensive industry, which inherently carries significant risks related to clinical trials, regulatory approvals, and market adoption.
Key Players & Entities
- Mesoblast Limited (company) — Registrant
- Silviu Itescu (person) — Chief Executive Officer and Executive Director
- October 20, 2025 (date) — Filing date of quarterly report
- September 30, 2025 (date) — End of reporting quarter
- Australian Securities Exchange (company) — Exchange where report was filed
FAQ
What type of report did Mesoblast Limited file on October 20, 2025?
Mesoblast Limited filed a quarterly report (Appendix 4C) for entities admitted on the basis of commitments.
For which period does the quarterly report provide information?
The quarterly report provides information for the quarter ended September 30, 2025.
Where are Mesoblast Limited's principal executive offices located?
Mesoblast Limited's principal executive offices are located at Level 38, 55 Collins Street, Melbourne, 3000, Australia.
Who is the Chief Executive Officer and Executive Director of Mesoblast Limited?
Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.
Under which act is Mesoblast Limited filing this report?
Mesoblast Limited is filing this report under the Securities Exchange Act of 1934.
Filing Stats: 229 words · 1 min read · ~1 pages · Grade level 18.1 · Accepted 2025-10-21 20:29:56
Filing Documents
- form6-kxpressreleasecoverf.htm (6-K) — 15KB
- exhibit991q1fy26appendix.htm (EX-99.1) — 27KB
- exhibit991q1fy26appendix001.jpg (GRAPHIC) — 254KB
- exhibit991q1fy26appendix002.jpg (GRAPHIC) — 268KB
- exhibit991q1fy26appendix003.jpg (GRAPHIC) — 195KB
- exhibit991q1fy26appendix004.jpg (GRAPHIC) — 118KB
- exhibit991q1fy26appendix005.jpg (GRAPHIC) — 127KB
- exhibit991q1fy26appendix006.jpg (GRAPHIC) — 178KB
- exhibit991q1fy26appendix007.jpg (GRAPHIC) — 201KB
- exhibit991q1fy26appendix008.jpg (GRAPHIC) — 175KB
- exhibit991q1fy26appendix009.jpg (GRAPHIC) — 137KB
- 0001345099-25-000088.txt ( ) — 2319KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated October 22, 2025 INDEX TO EXHIBITS Item 99.1 Appendix 4C of Mesoblast Ltd, dated October 20, 2025 .